[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Dr Lawrie, Ivermectin video, Short Precis", "description": "Ivermectin interview, Precis, Dr. Tess Lawrie\n\nVideo 1, the importance of EBP\nSynthesised evidence\n\nVideo 2, Ivermectin\nHeard publicity around Christmas / New Year\n\nFront line covid-19 critical care alliance\n\nhttps://covid19criticalcare.com\n\nDr. Pierre Kory\n\nDr. Lawrie has background expertise required for analysis\n\nWe / I do not prescribe\n\nImpressed with body of evidence from FLCCC\n\nSeveral plausible mechanisms of Ivermectin action, antiviral and anti-inflammatory\n\nPrevents viral life cycles and replication\n\nReduces inflammatory markers\n\nSome studies show Ivermectin reduces viral load\n\nStudies show possible action against yellow fever, dengue, zika and others\n\nLet\u2019s explore with more studies on viral illnesses\n\nPractical empirical evidence\n\nPreventing death and preventing infection\n\nIncluding RCT and better quality observational studies = 83% reduction in deaths\n\nAppraised each study for risk of bias\n\nTalked to authors\n\nReviewed manager software\n\nPooled studies and data\n\nSubmitted to Matt Hancock\u2019s office 4th Jan, no response\n\nPublications coming\n\nResearchers have a moral duty to relay information ASAP, so preprint site (2015)\n\nNext, RCT only\n\nStarting from scratch with a review team, 68% fewer deaths\n\nUsing very strict criteria\n\nForest plot\n\nPlotting deaths in treatment group and deaths in placebo group\n\nOut of 1,000 deaths\nIvermectin group, 27 deaths out of 1,000 cases\nPlacebo group, 82 deaths out of 903 cases\n\n65% reduction\n\nP = 0.002\n\nFindings of RCT was the same as observational studies\n\nUseful in all stages of the disease\n\n88% reductions in infection rates\n\nAnd mild and moderate disease to reduce viral load, so disease worsening\n\n? Long covid\n\nPossible evidence from Argentina and Peru\n\nPlacebo controlled trial for 2 weeks, with options to treat\n\nPlacebo controlled treatment trial, not ethical\n\nReduces symptoms, low certainty, 48%\n\nSafety\n\nBillions of doses have been given over 40 years\n\nWHO, essential medicines list\n\nThird of the world\u2019s population, 4,600 adverse events 16 deaths\n\n(Remdesivir, 417 deaths over past year)\n\nSafe at 10x dose\n\n3, 6, 12 mg tabs\n\n0.2 mg / Kg to 0.4 mg / Kg\n\nOral tabs\n\nCost, $168 per KG\n\nWHO, 100, 12mg tabs $2.90\n\nBIRD, recommended for prevention and treatment in UK, and told everyone, WHO, FDA etc.\n\nHelsinki declaration, doctors should give what they know to be effective\n\nLarge RCT would have to stop at interim analysis, probably at about 1,000 patients\n\nProtection from infection in workers and contacts\n\nIvermectin group, 25 out of 1,397 got covid\n\nControl group, 386 out of 833 got covid\n\nRisk reduction 93% reduction in infection rates\n\nOr 87% with the best study taken out\n\nMedical oil tankers\n\nIvermectin reduces the risk of death from COVID-19 -a rapid review and meta-analysis in support of the recommendation of the Front Line COVID-19 Critical Care Alliance.\n\nhttps://www.researchgate.net/publication/348297284_Ivermectin_reduces_the_risk_of_death_from_COVID-19_-a_rapid_review_and_meta-analysis_in_support_of_the_recommendation_of_the_Front_Line_COVID-19_Critical_Care_Alliance_Latest_version_v12_-_6_Jan_2021\n\nKory P, Meduri GU, Iglesias J, et al. Review of the emerging evidence demonstrating the efficacy of ivermectin in the prophylaxis and treatment of COVID-19. 18 Dec 2020.\nhttps://covid19criticalcare.com/wp-content/uploads/2020/11/FLCCC-Ivermectin-in-the-prophylaxis-and-treatment-of-COVID-19.pdf\n\nWorld Health Organization. 21st Model List of Essential Medicines. Geneva, Switzerland. 2019.\nhttps://www.who.int/publications/i/item/WHOMVPEMPIAU2019.06\n\nHiggins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 Cochrane, 2019.\nwww.training.cochrane.org/handbook. \n\nThe GRADE Working Group. GRADE [website] 2020\n www.gradeworkinggroup.org. \n\nAlam MT, Murshed R, Gomes PF, Masud ZM, Saber S, Chaklader MA, Khanam F, Hossain M, Momen ABIM, Yasmin N, Alam RF, Sultana A, Robin RC. Ivermectin as Pre-exposure Prophylaxis for COVID-19 among Healthcare Providers in a Selected Tertiary Hospital in Dhaka \u2013 An Observational Study", "link": "https://www.youtube.com/watch?v=ix8i7dfsCJg", "date_published": "2021-03-07 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Canada Update", "description": "Great Canadian update from Lindsay, thank you. \nFriendly Pharmacy 5: https://www.youtube.com/c/FriendlyPharmacy5\nVideos:\n\u2022 Vitamin D & Immunity: https://youtu.be/0dIAyLLhUFg\n\u2022 Oxford/AstraZeneca Vaccine: https://youtu.be/JNR79zDAyj0\n\u2022 COVID-19 VACCINE Q&A PART 1: Ingredients, Speed of Production, mRNA: https://youtu.be/l_LpsPKrxs0\n\n\u2022 Interval between vaccine doses stretched up to 4 months: https://www.cbc.ca/news/politics/naci-interval-advice-change-four-months-1.5934563\n\u2022 Health Canada Epidemiology summary: https://health-infobase.canada.ca/covid-19/epidemiological-summary-covid-19-cases.html\n\u2022 COVID-19 CANADA Vaccine Production: https://www.cp24.com/news/canada-signs-deal-to-produce-novavax-covid-19-vaccine-at-montreal-plant-1.5291842\n\u2022 COVID-19 Vaccines in Canada: https://www.canada.ca/en/public-health/services/diseases/coronavirus-disease-covid-19/vaccines.html?gclid=CPHSupaql-8CFYopfwodtzMF9w&gclsrc=ds", "link": "https://www.youtube.com/watch?v=pv43YHlc5xM", "date_published": "2021-03-06 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Evidence based practice, Dr Tess Lawrie", "description": "First part of a fascinating talk with Dr Tess Lawrie. Do come back for the second evidence based part. Thank you so much Dr. Lawrie, both for coming on this channel and for all of the life saving work you are doing.\nFollow the evidence, wherever it leads.", "link": "https://www.youtube.com/watch?v=UY92vb-9vEw", "date_published": "2021-03-06 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Ivermectin Evidence with Dr Tess Lawrie", "description": "Thank you very much Dr. Lawrie. \nIvermectin interview, Dr. Tess Lawrie\n\nIvermectin reduces the risk of death from COVID-19 -a rapid review and meta-analysis in support of the recommendation of the Front Line COVID-19 Critical Care Alliance.\n\nhttps://www.researchgate.net/publication/348297284_Ivermectin_reduces_the_risk_of_death_from_COVID-19_-a_rapid_review_and_meta-analysis_in_support_of_the_recommendation_of_the_Front_Line_COVID-19_Critical_Care_Alliance_Latest_version_v12_-_6_Jan_2021\n\nKory P, Meduri GU, Iglesias J, et al. Review of the emerging evidence demonstrating the efficacy of ivermectin in the prophylaxis and treatment of COVID-19. 18 Dec 2020.\nhttps://covid19criticalcare.com/wp-content/uploads/2020/11/FLCCC-Ivermectin-in-the-prophylaxis-and-treatment-of-COVID-19.pdf\n\nWorld Health Organization. 21st Model List of Essential Medicines. Geneva, Switzerland. 2019.\nhttps://www.who.int/publications/i/item/WHOMVPEMPIAU2019.06\n\nHiggins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 Cochrane, 2019.\nwww.training.cochrane.org/handbook. \n\nThe GRADE Working Group. GRADE [website] 2020\n www.gradeworkinggroup.org. \n\nAlam MT, Murshed R, Gomes PF, Masud ZM, Saber S, Chaklader MA, Khanam F, Hossain M, Momen ABIM, Yasmin N, Alam RF, Sultana A, Robin RC. Ivermectin as Pre-exposure Prophylaxis for COVID-19 among Healthcare Providers in a Selected Tertiary Hospital in Dhaka \u2013 An Observational Study\nhttps://ejmed.org/index.php/ejmed/article/view/599\n\nElgazzar A, Eltaweel A, Youssef SA, Hany B, Hafez M and Moussa H. Efficacy and Safety of ivermectin for Treatment and prophylaxis of COVID-19 Pandemic. Res. Square [Internet] 28Dec.2020\nhttps://www.researchsquare.com/article/rs-100956/v3\n\nChowdhury, ATMM, Shahbaz, M, Karim, MR, Islam, J, Guo, D, and He, SA Randomized Trial of Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin therapy on COVID19 patients.\nhttps://www.researchsquare.com/article/rs-38896/v1\n\nPodder CS, Chowdhury N, Mohim IS and Haque W. (2020). Outcome of ivermectin treated mild to moderate COVID-19 cases: a single-centre, open-label, randomised controlled study. IMC Journal of Medical Science. \n\nNiaee MS, Gheibi N, Namdar P, Allami A, Zolghadr L, Javadi A, et al. Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-centre clinical trial. Res. Square [Internet] 24Nov.2020\nhttps://www.researchsquare.com/article/rs-109670/v1\n\nHashim HA, Maulood MF, Rasheed AM, Fatak DF, Kabah KK, Abdulami AS, et al. Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq. medRxiv [Internet] 2020.10.26.20219345\nhttps://doi.org/10.1101/2020.10.26.20219345\n\nAhmed S, Karim MM, Ross AG, Hossain MS, Clemens JD, Sumiya MK, et al. A five day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. Int. J. Infect. Disease [Internet] 2Dec.2020.\nhttps://www.ijidonline.com/article/S1201-9712(20)32506-6/fulltext\n\nChachar AZK, Khan KA, Asif M, Tanveer K, Khaqan A and Basri R. Effectiveness of Ivermectin in SARS-CoV-2/COVID-19 Patients, Int. J. Sciences [Internet] Nov.2020:31-V1.2 6th January 2021 20 35\nhttps://www.ijsciences.com/pub/article/2378\n\nCepelowicz Rajter J, Sherman MS, Fatteh N, Vogel F, Sacks J and Rajter JJ. Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019. J. Chest [Internet] 27Oct.2020.\nhttps://journal.chestnet.org/action/showPdf?pii=S0012-3692%2820%2934898-4\n\nKhan SI, Khan SI, Debnath CR, Nath PN, Al Mahtab M, Nabeka H, et al. [Ivermectin Treatment May Improve the Prognosis of Patients With COVID-19.] Archivos de Bronconeumolog\u00eda, 2020. Volume 56, Issue 12, Pages 828-830,ISSN 0300- 2896.Spain.\nhttps://doi.org/10.1016/j.arbres.2020.08.007. \n\nGorial FI, Mashhadani S, Sayaly HM, Dakhil BD, AlMashhadani MM, Aljabory AM, et al. Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (Pilot Trial).MedRxiv. 2020.07.07.20145979;\nhttps://doi.org/10.1101/2020.07.07.20145979\n\nSpoorthi V, Sasank S. Utility of ivermectin and doxycycline combination for the treatment of SARS-CoV-2. International Archives of Integrated Medicine.\nhttps://www.iaimjournal.com/volume-7-issue-10- october-2020/\n\n\u201cI can\u2019t keep doing this.\u201d Doctor pleads for review of data during COVID-19 Senate hearing. 8 December 2020. \nhttps://www.youtube.com/watch?v=Tq8SXOBy-4w", "link": "https://www.youtube.com/watch?v=vYF8bnmdQfY", "date_published": "2021-03-06 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Medical exemptions and Ivermectin", "description": "Friendly Pharmacy 5: https://www.youtube.com/c/FriendlyPharmacy5\nVideos:\n\u2022 Vitamin D & Immunity: https://youtu.be/0dIAyLLhUFg\n\u2022 Oxford/AstraZeneca Vaccine: https://youtu.be/JNR79zDAyj0\n\u2022 COVID-19 VACCINE Q&A PART 1: Ingredients, Speed of Production, mRNA: https://youtu.be/l_LpsPKrxs0\n\n\u2022 Interval between vaccine doses stretched up to 4 months: https://www.cbc.ca/news/politics/naci-interval-advice-change-four-months-1.5934563\n\u2022 Health Canada Epidemiology summary: https://health-infobase.canada.ca/covid-19/epidemiological-summary-covid-19-cases.html\n\u2022 COVID-19 CANADA Vaccine Production: https://www.cp24.com/news/canada-signs-deal-to-produce-novavax-covid-19-vaccine-at-montreal-plant-1.5291842\n\u2022 COVID-19 Vaccines in Canada: https://www.canada.ca/en/public-health/services/diseases/coronavirus-disease-covid-19/vaccines.html?gclid=CPHSupaql-8CFYopfwodtzMF9w&gclsrc=ds\nIVERMECTIN:\n\u2022 US National Library of Medicine: https://medlineplus.gov/druginfo/meds/a607069.html\n\u2022 Pharmacokinetic considerations on the repurposing of ivermectin for treatment of COVID\u201019: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7404744/\n\nhttps://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(20)30464-8/fulltext", "link": "https://www.youtube.com/watch?v=VS2-QxAM41Y", "date_published": "2021-03-06 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]